Serum Exosomal miRNA-1226 as Potential Biomarker of Pancreatic Ductal Adenocarcinoma.
exosome
miRNA
miRNA-1226-3p
pancreatic ductal adenocarcinoma
Journal
OncoTargets and therapy
ISSN: 1178-6930
Titre abrégé: Onco Targets Ther
Pays: New Zealand
ID NLM: 101514322
Informations de publication
Date de publication:
2021
2021
Historique:
received:
15
12
2020
accepted:
08
02
2021
entrez:
5
3
2021
pubmed:
6
3
2021
medline:
6
3
2021
Statut:
epublish
Résumé
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-related mortality and it is urgent to find biomarkers for early detection of PDAC. Exosomal miRNAs are useful biomarkers for cancer detection. The aims of this study were to investigate the potential role of serum exosomal miRNA in detection of PDAC and to analyze the correlation between the levels of exosome miRNA and the tumor biological behaviors. Thirteen serum samples were collected from five patients with PDACs, three healthy individuals (HIs) and five benign pancreatic lesions (BP) for a high throughput profiling analysis to identify an altered miRNA expression patterns in PDAC. Candidate exosomal miRNAs were filtered based on a second independent cohort that included 17 PDACs and 12 benign pancreatic lesions by quantitative real-time polymerase chain reaction (qRT-PCR). Four miRNAs were selected for miRNA validation as PDAC biomarkers in a subsequent set of samples. The association between candidate exosomal miRNA and tumor behavior (tumor invasion or metastases) was evaluated in 17 PDACs. In vitro studies were performed to evaluate the role of candidate exosomal miRNA on cell viability, apoptosis and cell migration in two PDAC cell lines. The expression of 11 miRNAs showed same trend between PDAC and BP, and between PDAC and HIs. Six of them were upregulated (miR-203b-5p, miR-342-5p, miR-337-5p, miR-149-5p, miR-877-5p, miR-203a-3p), and five were downregulated (miR-1226-3p, miR-3182, miR-625-3p, miR-624-5p, miR-664a-5p). miR-1226-3p was selected as the candidate exosomal biomarker for the PDAC detection. The expression of serum exosomal miRNA-1226-3p was downregulated in PDACs compared to the BPs (p = 0.025). miR-1226-3p had acceptable performance in predicting [area under the curve (AUC) = 0.74] PDAC. Exosomal miRNA-1226-3p level in PDAC with invasion or metastases was lower than that without invasion or metastases (p = 0.028). Transfection of miRNA-1226-3p significantly inhibited the proliferation of PANC-1 and BXP-3 cells, stimulated cell apoptosis and inhibited cell migration. Serum exosomal miRNA-1226-3p is a potential biomarker in diagnosing and predicting the tumor invasion or metastases of PDAC.
Sections du résumé
BACKGROUND
BACKGROUND
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-related mortality and it is urgent to find biomarkers for early detection of PDAC. Exosomal miRNAs are useful biomarkers for cancer detection. The aims of this study were to investigate the potential role of serum exosomal miRNA in detection of PDAC and to analyze the correlation between the levels of exosome miRNA and the tumor biological behaviors.
MATERIALS AND METHODS
METHODS
Thirteen serum samples were collected from five patients with PDACs, three healthy individuals (HIs) and five benign pancreatic lesions (BP) for a high throughput profiling analysis to identify an altered miRNA expression patterns in PDAC. Candidate exosomal miRNAs were filtered based on a second independent cohort that included 17 PDACs and 12 benign pancreatic lesions by quantitative real-time polymerase chain reaction (qRT-PCR). Four miRNAs were selected for miRNA validation as PDAC biomarkers in a subsequent set of samples. The association between candidate exosomal miRNA and tumor behavior (tumor invasion or metastases) was evaluated in 17 PDACs. In vitro studies were performed to evaluate the role of candidate exosomal miRNA on cell viability, apoptosis and cell migration in two PDAC cell lines.
RESULTS
RESULTS
The expression of 11 miRNAs showed same trend between PDAC and BP, and between PDAC and HIs. Six of them were upregulated (miR-203b-5p, miR-342-5p, miR-337-5p, miR-149-5p, miR-877-5p, miR-203a-3p), and five were downregulated (miR-1226-3p, miR-3182, miR-625-3p, miR-624-5p, miR-664a-5p). miR-1226-3p was selected as the candidate exosomal biomarker for the PDAC detection. The expression of serum exosomal miRNA-1226-3p was downregulated in PDACs compared to the BPs (p = 0.025). miR-1226-3p had acceptable performance in predicting [area under the curve (AUC) = 0.74] PDAC. Exosomal miRNA-1226-3p level in PDAC with invasion or metastases was lower than that without invasion or metastases (p = 0.028). Transfection of miRNA-1226-3p significantly inhibited the proliferation of PANC-1 and BXP-3 cells, stimulated cell apoptosis and inhibited cell migration.
CONCLUSION
CONCLUSIONS
Serum exosomal miRNA-1226-3p is a potential biomarker in diagnosing and predicting the tumor invasion or metastases of PDAC.
Identifiants
pubmed: 33664577
doi: 10.2147/OTT.S296816
pii: 296816
pmc: PMC7924134
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1441-1451Informations de copyright
© 2021 Wang et al.
Déclaration de conflit d'intérêts
There are no conflicts of interest to declare.
Références
Eur Urol Focus. 2018 Apr;4(3):412-419
pubmed: 28753793
Cell Immunol. 2014 Nov-Dec;292(1-2):65-9
pubmed: 25290620
Biochem Pharmacol. 2012 Jun 1;83(11):1484-94
pubmed: 22230477
Curr Opin Cell Biol. 2014 Aug;29:116-25
pubmed: 24959705
World J Gastroenterol. 2015 Jul 28;21(28):8527-40
pubmed: 26229396
Cancer Lett. 2009 Oct 8;283(2):168-75
pubmed: 19401262
Front Oncol. 2019 Apr 30;9:330
pubmed: 31114758
Gastroenterology. 2014 Jan;146(1):291-304.e1
pubmed: 24355035
Breast Cancer Res. 2016 Sep 08;18(1):90
pubmed: 27608715
Oncol Rep. 2017 Oct;38(4):2182-2188
pubmed: 28849236
Int J Mol Sci. 2013 Jul 16;14(7):14785-99
pubmed: 23863690
J Thorac Oncol. 2013 Sep;8(9):1156-62
pubmed: 23945385
Int J Mol Sci. 2019 Sep 04;20(18):
pubmed: 31487880
J Natl Cancer Inst. 2019 Apr 1;111(4):372-379
pubmed: 30137376
Cell Physiol Biochem. 2016;39(5):1716-1722
pubmed: 27639768
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
J Clin Oncol. 2009 Nov 20;27(33):5660-9
pubmed: 19858397
Int J Cancer. 2015 Jun 1;136(11):2616-27
pubmed: 25388097
Adv Exp Med Biol. 2015;867:247-60
pubmed: 26530370
Cancer Res. 2014 Jun 1;74(11):2913-21
pubmed: 24840647
Oncotarget. 2017 Aug 18;8(44):77028-77040
pubmed: 29100367
J Urol. 2016 May;195(5):1331-1339
pubmed: 26714199
J Cell Biol. 1985 Sep;101(3):942-8
pubmed: 2993317
BMC Cancer. 2018 Jan 31;18(1):116
pubmed: 29385987
Int J Oncol. 2010 Jul;37(1):61-9
pubmed: 20514397
Cancer J. 2017 Nov/Dec;23(6):333-342
pubmed: 29189329
Ann Surg Oncol. 2010 Dec;17(12):3120-8
pubmed: 20652642
Clin Transl Gastroenterol. 2019 Apr;10(4):e00029
pubmed: 31009404
Medicine (Baltimore). 2018 Aug;97(35):e12132
pubmed: 30170450
Semin Cell Dev Biol. 2018 Jun;78:13-21
pubmed: 28803894
Clin Chem. 2012 Mar;58(3):610-8
pubmed: 22194634
Dis Markers. 2018 May 15;2018:6292396
pubmed: 29887920
Mol Oncol. 2019 Feb;13(2):212-227
pubmed: 30358104
Cell Physiol Biochem. 2018;51(2):610-629
pubmed: 30458449
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
JAMA. 2007 May 2;297(17):1901-8
pubmed: 17473300
Exp Cell Res. 2019 Jun 1;379(1):30-47
pubmed: 30894280
Nature. 2015 Jul 9;523(7559):177-82
pubmed: 26106858
Visc Med. 2017 Mar;33(1):36-41
pubmed: 28612015
Oncol Lett. 2018 May;15(5):7479-7488
pubmed: 29731898
Acta Radiol. 2019 Oct;60(10):1216-1223
pubmed: 30678482
Ann Surg Oncol. 2019 Jul;26(7):2104-2111
pubmed: 30820789